New reflux disease technology more comfortable, not more effectiveJuly 11, 2006A wireless device that measures the acidity of stomach contents backwashed into the esophagus allows patients to avoid some of the nose pain and throat discomfort associated with the conventional wired monitor used to manage hard-to-treat gastroesophageal reflux disease. However, while the new technology appears be better tolerated, no studies showed that it was better for diagnosing or managing these patients, said David Mark, M.D., lead author of a new review of evidence on wireless esophageal pH monitoring for gastroesophageal reflux disease, or GERD. The systematic review was conducted by the Blue Cross and Blue Shield Association's Technology Evaluation Center, which analyzes clinical and scientific evidence to evaluate whether a technology improves health outcomes. Physicians turn to pH monitoring — wireless or wired — for patients who have not responded to standard GERD therapy. The procedure is also used in preoperative evaluation to choose patients who will benefit most from surgery. "After our survey of all the ways this wireless device has been studied, basically we can conclude that it was more comfortable than the wired device, that the diagnostic capacity of the wired and wireless devices seem to be similar and that there's no evidence that 48 hours was better than 24 hours," said Mark, associate director of the Technology Evaluation Center. In conventional pH monitoring, a probe attached to a catheter is snaked through the nose and down the throat to the esophagus, the tube that carries food from the throat to the stomach. The probe and wires typically stay in place for 24 hours to send back information to a portable data recorder worn by the patient. A specialist analyzes that information to learn how often caustic stomach acid flows into the esophagus. "You're talking about a device that's kind of unsightly for the day that you are using it, and it's definitely irritating to your sinuses and your nose," Mark said. The newest pH monitoring technology works through a wireless probe that is clipped to the muscular valve at the lower part of the esophagus. Mark's team gathered research on wireless pH monitoring to evaluate some of its purported advantages, including whether the wireless test leads to better diagnosis because patients — uninhibited by the catheter — follow more natural eating habits and physical behavior. They compared the quality of data yielded from 48-hour sessions with the wireless monitor to 24-hour sessions that are standard with wired monitors. Gastroenterologist Jed Weissberg is a physician-consultant who commented on the review of evidence. "It takes training and experience to interpret the physiological data," he said. "Traditionally, physicians have had 24 hours worth of data to interpret. With the wireless capsule, there is the possibility of having more extended data collection. That's an intriguing extension to the technique, though its impact on clinical management has not yet been carefully studied." Of the nine studies included in the TEC review, two measured comfort. The more convincing was a randomized study that compared patients assessed with the wireless device with another group assessed with the wired probe. Patients implanted with the wireless device reported chest discomfort more often, but reported greater satisfaction and less interference with daily life activities. "So you are trading 80 to 90 percent chance of nose pain and throat discomfort for about a 30 to 40 percent chance of having some discomfort behind your sternum," Mark said. Mark said the TEC review found no studies that convincingly showed wireless pH monitoring is superior to wired technology. The evidence evaluating the effectiveness of the conventional, wired device is limited and weak, Mark said. So when you have evidence of the standard device that is equivocal, it is difficult to say whether the new technology is better at improving patient health, he added. Weissberg said that the TEC special report was also complicated by the fact that there is no gold-standard diagnostic test for GERD. Reflux is usually diagnosed based on signs and symptoms and by how patients respond to medications or treatments that have worked in others with GERD. There's no test to double-check the accuracy of the new technology, but after surveying the evidence, Mark's team concludes that the diagnostic performance seems to be about the same for the wired and wireless monitors. The review also found a strong technical track-record for implanting the wireless probe and getting it to stay in place. "The studies seemed to show that, by and large, they are pretty successful in placing the device 95 to 100 percent of the time," Mark said. "Ideally you'd like the device to stay in place 24 to 48 hours, but sometimes it becomes loose and stops recording properly. The success rate of 48 hours is somewhere between 90 and 98 percent," he said. But, Mark said, there's no firm evidence that leaving the probe in longer leads to better health, or more accurate diagnosis for the patient. Center for the Advancement of Health |
|||||||||||||||||||||
| Related Reflux Disease Current Events and Reflux Disease News Articles Reflux esophagitis due to immune reaction, not acute acid burn, UT Southwestern researchers report Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study. Commentary warns of unexpected consequences of proton pump inhibitor use in reflux disease Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Barrett's esophagus patients have same survival rates as general population New Mayo Clinic research has found that survival rates of patients with Barrett's esophagus, which can be a precursor for esophageal cancer, are no different than the survival rates for the general population. GERD negatively impacts sleep quality, results in considerable economic burden There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. GERD patient satisfaction hinges on medication type and physician bedside manner Patient satisfaction with their medications and the quality of interactions with their doctor reflect the success of gastroesophageal reflux disease (GERD) therapy, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. University of Saskatchewan and Canadian Synchrotron researchers shed light on esophageal disease Canadian Light Source (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron's infrared microscope to identify tissue afflicted with a condition known as Barrett's Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. NEJM study finds radiofrequency ablation can reverse Barrett's esophagus, reduce cancer risk Patients who have gastroesophageal reflux disease (GERD) for a prolonged period have an increased risk of developing Barrett's esophagus, a pre-cancerous condition where the tissue lining the esophagus becomes damaged by stomach acid and transformed into something like the inside of the stomach. Obesity predicts inadequate bowel prep at colonoscopy Obesity is an independent predictor of inadequate bowel preparation at colonoscopy, and the presence of additional risk factors further increases the likelihood of a poorly cleansed colon. Technique eradicates problems in most patients with Barrett's esophagus A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress. Use of acid-suppressive medications associated with increased risk of hospital-acquired pneumonia Hospitalized patients who receive acid-suppressive medications such as a proton-pump inhibitor have a 30 percent increased odds of developing pneumonia while in the hospital. More Reflux Disease Current Events and Reflux Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||